Vol 51, No 4 (2020)
Untitled
Published online: 2020-12-01

open access

Page views 270
Article views/downloads 558
Get Citation

Connect on Social Media

Connect on Social Media

Clinical characteristics of essential thrombocythemia patients depend on the mutation status

Witold Prejzner1, Andrzej Mital1, Maria Bieniaszewska1, Aleksandra Leszczyńska1, Agata Szymańska1, Michał Czarnogórski1, Andrzej Hellmann1
DOI: 10.2478/ahp-2020-0040
Acta Haematol Pol 2020;51(4):230-235.

Abstract

The impact of the mutation status on the clinical course and the outcome of essential thrombocythemia (ET) patients has not yet been completely established. A total of 171 patients with diagnosed ET were tested and subsequently grouped, according to their mutation status – Janus Kinase 2 () – 112 patients, calreticulin () – 36 patients, and thrombopoietin receptor () – 5 patients. Moreover, 18 individuals were triple-negative (with non-mutated , , and ). -mutated patients preferentially were male, with higher platelets (PLT) counts (mean PLT = 1 002.3) and lower hemoglobin and hematocrit levels at the diagnosis, compared to the (mean PLT = 933.6), (mean PLT = 940.8) and triple-negative patients (mean PLT = 822.6) ( = 0.0035). The patients with mutated, and the triple-negative ones had a lower risk of arterial and venous thrombosis (3% and 5.6% cases at the time of diagnosis, respectively) than the patients with mutation (7.2%) ( = 0.9210). The overall survival rate did not differ statistically between the groups.

Article available in PDF format

View PDF Download PDF file